UNCLASSIFIED

Lawrence Livermore National Laboratory

Institutional Biosafety Committee

IBC Meeting Minutes

Meeting Date	4.14.2026
Call to Order	1:29 PM
Adjourned	1:49 PM
Meeting Type	Hybrid: WebEx & In-Person All IBC Meetings are closed in accordance with the *LLNL IBC Policy on Public Information*.
Quorum	The IBC has eleven voting members. Six members, including at least one non-affiliated member, are required for a quorum.
Next Meeting Date	5.12.2026

Committee Member	Attendance	Late Arrival	Early Departure
Amy Rasley	Yes		
Bruce Mackinlay	Yes		
Bruce Wolfe	Yes		
Carolyn Hall	Yes		
Ed Saada	Yes		
Mike Malfatti	Yes		
Mimi Yung	Yes	1:33 PM	
Monica Borucki	Yes		
Natalie Jouravel	No		
Nick Watkins	Yes		
Rebecca MacIsaac	Yes	1:33 PM	

Non-Voting Attendees	
Attendee	**Attendance**
Elizabeth Zukoski	No
Gina Alvino	Yes
Julie Avila	Yes
Kul Garg	No
Michael Rodriguez	No
Rachel Brown	No
Tamara Mercante	Yes
Wes Overton	Yes

Protocol for Review	
PI Name	Arrildt, Kate
Presenter Name	Arrildt, Kate
Application Number	2023-011
Title	Building a Computational and Experimental Rapid Response Pipeline to Counter Emerging Biothreats
Type of Review	☐ New Application ☐ Amendment/Annual Review ☒ 3YR Renewal
Highest Risk Group Level	☐ RG1 ☒ RG2 ☐ RG3
Highest Containment Level	☐ BSL1 ☒ RG2 ☐ RG3
Applicable NIH Guidelines	III-D-2-a, III-E
Discussion & Questions	• A.1.1. remove reference to lentiviral particles • On pg. 3, there is a description of in vitro testing with live viruses but there are no viruses listed on this protocol. PI indicated they are considering using virus-like particles but don't have a clear vision for this work. Committee suggested removing references to this type of work until they have a better idea of what they are going to be doing. • Move biological agents/materials not being actively used under this BUA to an ASBM then update some of the A.2.4 questions at the same time. • Do not delete 1662 from WCD section. • The PI lists recombinant spike protein from SARS-CoV-1 in Section B.1.1 and that this will come from both LLNL and commercial sources. Therefore, the PI needs to also list this spike protein in Section B.1.6 as a gene that will be expressed recombinantly onsite under this BUA, so add to B.1.6 as genes that are going to be expressed. • Section B.1.6 - the committee asked the PI if the genes and proteins listed were the only ones that were being recombinant expressed or produced in-house and that all of the other recombinantly expressed proteins listed in B.1.1. were coming from outside vendors. The PI confirmed that is accurate. The committee reminded the PI that if this changes in the future and some of the other proteins would be expressed in-house that this could impact the specific sections of the NIH Guidelines that applied to work covered by this BUA.
IBC Vote	**Motion:**

	☐ Approved ☒ Approved with Amendment: **Required Amendment** • Uncheck 3-D-1-A in NIH guidelines • Uncheck A.2.7 • A.1.1. Remove reference to lentiviral particles • Remove unused biological materials and update A.2.4 • Add genes that are going to be expressed to B.1.6. Motion made by: Carolyn Hall Motion seconded by: Bruce Mackinlay **Votes** • For: 7 • Against: 0 • Abstain: 0 • Recused (include names): Ed Saada **Conflict(s) of Interest:** Ed Saada

Committee Business	
New Business	**Biological Use Authorization Review Policy** **Motion:** ☐ Approved ☒ Approved with Amendment: **Required Amendment** • Remove highlighted green box for Figures 3, 5, and 6 Motion made by: Mike Malfatti Motion seconded by: Ed Saada

	Votes • For: 8 • Against: 0 • Abstain: 0 • Recused (include names): N/A **Conflict(s) of Interest:** N/A
Educational Opportunity	N/A
Review of Previous Meeting Minutes	**Motion:** ☐ Approved ☒ Approved with Amendment: **Required Amendment** • Reworded the language regarding the HSD question on the TB testing or immunization to add transparency. • Strike the second bullet point on the discussion notes from BUA 2022-010 as it didn't accurately reflect the conversation. • Update the language regarding the grant information on BUA 2022-010 to read: "The newly proposed project uses a name that is not an acronym and is intended to serve solely as a unique identifier." • Added transparency in language regarding discussion of lowering the containment level for BUA 2017-006. • Updated language regarding discussion of vaccine for BUA 2017-006. • Correct misspelling of staff member's name in area documenting attendance. Motion made by: Monica Borucki Motion seconded by: Mimi Yung **Votes** • For: 7 • Against: 0 • Abstain: 1 • Recused (include names): N/A

	Conflict(s) of Interest: N/A

This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.